Abstract: Osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, the coprecipitate being in divided form, are described. Kits are also described, as are a process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide.
Abstract: A polysaccharide comprising carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical: the hydrophobic radical being a residue of a hydrophobic alcohol having a linear, branched or cyclic alkyl chain containing at least 6 carbon atoms, the hydrophobic radical being bonded to a linker arm R by a function G, the linker arm R being bonded to a carboxyl function of the polysaccharide by a bond F, R being an at least divalent radical of a chain including between 1 and 15 carbons, which is optionally branched and/or unsaturated, optionally including one or more heteroatoms, chosen amongst O, N and/or S, F being an amide function, G being a carbamate function, the unsubstituted carboxyl functions of the polysaccharide being in the form of a cation carboxylate, said cation being chosen amongst alkali metal cation.
Type:
Application
Filed:
March 15, 2013
Publication date:
September 19, 2013
Applicant:
ADOCIA
Inventors:
Remi Soula, Olivier Soula, Gerard Soula, Richard Charvet, David Duracher
Abstract: A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable.
Abstract: Osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, the coprecipitate being in divided form, are described. Kits are also described, as are a process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide.
Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.
Abstract: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.
Type:
Grant
Filed:
April 5, 2010
Date of Patent:
April 23, 2013
Assignee:
Adocia
Inventors:
Remi Soula, Olivier Soula, Gerard Soula, Richard Charvet
Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.
Type:
Application
Filed:
August 9, 2012
Publication date:
March 14, 2013
Applicant:
ADOCIA
Inventors:
Olivier SOULA, Gérard SOULA, Jeff TONNAR
Abstract: The invention relates to an amphiphilic-BMP polymer complex which is physically and chemically stable and soluble in water, characterized in that: the amphiphilic polymers comprise a hydrophilic polysaccharide skeleton functionalized with hydrophobic substituents and hydrophilic groups the BMP is selected from the group of therapeutically active BMPs (Bone morphogenetic Proteins), the polymer/BMP mass ratio is lower than or equal to 700. The invention also relates to the process for preparing the amphiphilic-BMP polymer complex in an aqueous medium and in the absence of organic solvents likely to denature the protein. The invention also relates to therapeutic compositions of an amphiphilic-BMP polymer complex according to the invention.
Abstract: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.
Type:
Grant
Filed:
September 28, 2009
Date of Patent:
February 5, 2013
Assignee:
Adocia
Inventors:
Olivier Soula, Remi Soula, Martin Gaudier, Gerard Soula
Abstract: The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: —R1-[[AA]-[R2]n]m??formula I It also relates to a pharmaceutical composition characterized in that it comprises an oligosaccharide according to the invention and an active ingredient is chosen from the group consisting of proteins, glycoproteins, peptides and non-peptide therapeutic molecules.
Type:
Application
Filed:
May 10, 2012
Publication date:
December 6, 2012
Applicant:
ADOCIA
Inventors:
Richard CHARVET, Remi SOULA, Olivier SOULA
Abstract: An anionic polysaccharide comprising carboxylic acid functional groups of formula I: in which: the polysaccharide may be either, synthetic or modified, i represents the degree of functionalization of the hydroxyls, j represents the degree of functionalization of the hydroxyls, L and Q represent an optionally branched and/or unsaturated chain comprising from 1 to 15 carbons, F is a functional group chosen from the group consisting of the carbamate functional group, the carbonyl being bonded to the Q radical, the ester functional group, the carbonyl being bonded to the Q radical, the amide functional group, the carbonyl being bonded to the Q radical, and the carboxylate functional group, and Grp is chosen from the group consisting of a mono- or divalent cation and of a chain comprising from 4 to 50 carbons.
Type:
Application
Filed:
May 10, 2012
Publication date:
November 22, 2012
Applicant:
ADOCIA
Inventors:
Richard CHARVET, Guilhem MORA, Rémi SOULA
Abstract: Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.
Type:
Grant
Filed:
May 23, 2011
Date of Patent:
August 14, 2012
Assignee:
Adocia
Inventors:
Latifa Dahri-Correia, Jose Correia, Guy Dubreucq, David Duracher, Remi Soula, Olivier Soula, Gerard Soula
Abstract: A complex between an insulin and a polysaccharide comprising carboxyl functional groups is described, the polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, the phenylalanine derivative being chosen from phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and the insulin being either a human insulin or an insulin analog. A pharmaceutical composition including at least one complex, especially in the form of an injectable solution, is also described.
Abstract: Dextran of the following general formula I: is described, wherein R represents a chain containing from 1 to 15 carbon atoms and having at least one acid functional group prior to attachment to AA, the chain optionally being branched and/or unsaturated and containing one or more heteroatoms, such as O, N or/and S, F represents an ester, a carbamate or an ether, AA represents a hydrophobic amino acid radical, L or D, derived from a coupling between an amine of an amino acid and at least one acid functional group of R; the amino acid, prior to attachment to R, being selected from the group consisting of tryptophan, phenylalanine, leucine, isoleucine, alanine and valine, and alcohol, amide or decarboxylated derivatives thereof, and alkaline cation salts thereof, i represents the molar fraction of substituent F—R-[AA]n per glycosidic unit and is from 0.1 to 2, n represents the molar fraction of R groups substituted by AA and is from 0.
Type:
Application
Filed:
September 30, 2011
Publication date:
February 16, 2012
Applicant:
ADOCIA
Inventors:
Gerard SOULA, Olivier Soula, Remi Soula, Richard Charvet
Abstract: Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.
Type:
Application
Filed:
May 23, 2011
Publication date:
December 8, 2011
Applicant:
ADOCIA
Inventors:
Latifa Dahri-Correia, Jose Correia, Guy Dubreucq, David Duracher, Remi Soula, Olivier Soula, Gerard Soula
Abstract: Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one active principle are provided.
Type:
Application
Filed:
February 9, 2011
Publication date:
August 11, 2011
Applicant:
ADOCIA
Inventors:
Richard CHARVET, Remi SOULA, Olivier SOULA
Abstract: A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical.
Type:
Application
Filed:
November 19, 2010
Publication date:
July 21, 2011
Applicant:
ADOCIA
Inventors:
Remi SOULA, Olivier SOULA, Gerard SOULA, Richard CHARVET, David DURACHER
Abstract: A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them.
Type:
Application
Filed:
December 23, 2010
Publication date:
July 14, 2011
Applicant:
ADOCIA
Inventors:
Richard CHARVET, Remi SOULA, Olivier SOULA
Abstract: An open implant constituted of an osteogenic composition comprising at least one osteogenic growth factor/amphiphilic anionic polysaccharide complex, one soluble salt of a cation at least divalent, and one organic support, said organic support comprising no demineralized bone matrix. In one embodiment, said implant is in the form of a lyophilizate. It also relates to the method for the preparation thereof.
Abstract: Polysaccharide including carboxyl functional groups. The polysaccharide being chosen from the group of anionic synthetic polysaccharides including 1,6 bonds obtained from neutral polysaccharides of which at least one of a carboxyl functional groups is esterified by a hydrophobic alcohol (-Ah) (residue of a hydrophobic alcohol). The hydrophobic alcohol (Ah) being grafted or bonded to the anionic polysaccharide by a function F (ester function), which results from coupling between the carboxylate function of the anionic polysaccharide and hydroxyl function of the hydrophobic alcohol. Carboxyl functions of anionic polysaccharide, which are not substituted, are in the form of carboxylate of a cation. The polysaccharide including carboxyl functional groups are amphiphilic at neutral pH. It also relates to its use for the preparation of pharmaceutical compositions and the pharmaceutical compositions comprising a polysaccharide and at least one active principle.
Type:
Application
Filed:
November 10, 2010
Publication date:
May 12, 2011
Applicant:
ADOCIA
Inventors:
Richard CHARVET, Remi SOULA, Olivier SOULA